King's College London

Research portal

Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders

Research output: Contribution to journalArticle

Carmine Maria Pariante, Gayle M. Wittenberg, Annie Stylianou, Yun Zhang, P. S. Jagannatha, Yu Sun, Dai Wang, Benjamin Hsu, Mark E. Curran, Shahid Khan, Ye-Guang Chen, Edward T. Bullmore, Wayne C. Drevets

Original languageEnglish
Article numberdoi.org/10.1038/s41380-019-0471-8
JournalMolecular Psychiatry
Publication statusPublished - 19 Sep 2019

King's Authors

Abstract

Activation of the innate immune system is commonly associated with depression. Immunomodulatory drugs may have efficacy for depressive symptoms that are co-morbidly associated with inflammatory disorders. We report a large-scale reanalysis
by standardized procedures (mega-analysis) of patient-level data combined from 18 randomized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders (N =10,743 participants). Core depressive symptoms (low mood, anhedonia) were measured by the Short Form Survey (SF-36) or the Hospital Anxiety and Depression Scale (HADS), and participants were stratified into high (N =1921) versus low-depressive strata based on baseline ratings. Placebocontrolled change from baseline after 4–16 weeks of treatment was estimated by the standardized mean difference (SMD) over all trials and for each subgroup of trials targeting one of 7 mechanisms (IL-6, TNF-α, IL-12/23, CD20, COX2, BLγS, p38/MAPK14). Patients in the high depressive stratum showed modest but significant effects on core depressive symptoms (SMD = 0.29, 95% CI [0.12–0.45]) and related SF-36 measures of mental health and vitality. Anti-IL-6 antibodies (SMD = 0.8, 95% CI [0.20–1.41]) and an anti-IL-12/23 antibody (SMD =0.48, 95% CI [0.26–0.70]) had larger effects on depressive
symptoms than other drug classes. Adjustments for physical health outcome marginally attenuated the average treatment effect on depressive symptoms (SMD =0.20, 95% CI: 0.06–0.35), but more strongly attenuated effects on mental health and
vitality. Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment. Novel immune-therapeutics can produce antidepressant effects in depressed patients with primary
inflammatory disorders that are not entirely explained by treatment-related changes in physical health.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454